INO · Inovio Pharmaceuticals, Inc.
AI read · Good for INO
The AI's read
A higher target and continued Buy rating show Jefferies sees more potential in Inovio. This is an analyst's view, not proof that a drug, trial, or sales result has changed.
Jefferies says to keep buying Inovio Pharmaceuticals and has raised its price target to $8.
Good for INO
Jefferies kept its Buy rating on Inovio and raised its share price target from $3 to $8. The stronger analyst view is favorable, but the report gives no new company results.
Get alerts for INO
Follow Inovio Pharmaceuticals, Inc. (INO) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for INOFree on the App Store and Google Play, or on the web.